|
|
胰岛素抵抗与高血压的关系研究进展http://www.51kang.com
2008-1-15 9:39:57 第四届中国健康产业论坛组委会
4、问题与展望
胰岛素抵抗和高血压的发生均为多因素,进一步的临床研究应区分各种情况如高胰岛素血症和低胰岛素血症。而在临床实践中对于代谢综合征高血压患者,建议联合应用增加胰岛素敏感性的药物,部分病例甚至可以考虑单用，应综合考虑效益与风险之间的关系并结合患者的情况,治疗需个体化，进一步的研究可能为高血压病及其他心脑血管病的全面治疗带来新的变化。
参考文献
1. Ginsberg HN. Insulin resistance and cardiovascular disease[J].Clin Invest, 2002, 106(5): 453。
2. Guo X, Cheng S, Taylor KD,et al.Hypertension genes are genetic markers for insulin sensitivity and resistance [J]. Hypertension, 2005,45:799-803.
3. Verma S, Bhanot S, McNeill JH. Sympathectomy prevents fructose-induced hyperinsulinemia and hypertention[J]. Eur J Pharmacol, 1999, 373:R1-4.
4. Nagai M, Kamide K, Rakugi H,et al. Role of endothelin-1 induced by insulin in the regulation of vascular cell growth[J]. Am J Hypertens, 2003,16:223-228.
5. Dhalla NS, Temsah RM, Netticadan T.Role of oxidative stress in cardiovascular diseases[J]. J Hypertens, 2000, 18: 655-673.
6. Koji K, Regulation of endothelial constitutive nitric oxide synthase gene expression in endothelial cell and in Vivo[J].Circulation, 2000, 101(6):677-678.
7. Tsuda K, Kinoshita Y, Nishio I, et al. Hyperinsulinemia is a determinant of membrance fluidity of erythrocytes in essential hypertension[J]. Am J Hypertens, 2001, 14(5Pt1):419-423.
8. Taddei S, Virdis A, Ghiadoni L, et al. Effects of antihypertensive drugs on endothelial dysfunction: Clinical implications[J]. Drugs, 2002, 62(2):265-284.
9. Haenni A, Lind L, Reneland R, et al. Blood pressure changes in relations to sodium and calcium status in induced hyperinsulinemia[J]. Blood Press, 2002, 9(2):116-120.
10. Tsai YS, Kim HJ, Takahashi N,et al. Hypertension and abnormal fat distribution but not insulin resistance in mice with P465L PPAR-gamma[J]. J Clin Invest, 2004,114:240-249.
11. Raji A, Seely EW, Bekins SA,et al. Rosiglitazone improves insulin sensitivity and lowers blood pressure in hypertensive patients[J]. Diabetes Care, 2003,26:172-178.
12. SchafersRF.Do effectson blood pressure contribute to improved clinical outcomes with metformin[J] Diabetes Metab,2003,29:6S62-6S70.
13. Manzella D, Grella R, EspositoK,et al. Blood pressure and cardiac autonomic nervous system in obese type 2 diabetic patients: effect of metformin administration[J]. Am J Hypertens, 2004,17:223-227.
14. ALLHATOfficers and Coordinatorsforthe ALLHATCollaborative Research Group. The Antihypertensive and Lipid-LoweringTreatment to Prevent Heart Attack Trial. Major outcomes in moderately hypercholesterolemic, hypertensive patients randomized to pravastatin vs usual care: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT-LLT) [J].JAMA,2002,288:2998-3007.
15. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The heart outcome prevention evaluation study investigators [J]. N Engl J Med, 2000, 342 (3) : 145-153.
16. Masuo K, Mikami H, Ogihara T, et al. Weight reduction and pharmacologic treatment in obese hypertensives[J]. Am J Hypertens, 2001, 14(32):530-538.
17. Anan F, Takahashi N, Ooie T, et al. Candesartan, an angiotensin II receptor blocker, improves left ventricular hypertrophy and insulin resistance[J]. Metabolism, 2004, 53(6):777-781.
18. Inukai T, Inukai Y, Matsutomo R, et al. Clinical usefulness of doxazosin in patients with type 2 diabetes complicated by hypertension: effects on glucose and lipid metabolism[J]. J Int Med Res, 2004, 32(2):206-213.
19. Lithell HO. Insulin resistance and diabetes in the context of treatment of hypertension[J]. Blood Press, 1998,3:28-31.
20. Goyal RK. Hypertension and insulin resistence in hypertension: differential effect of antihypertension agents[J]. Clin Exp Hyperters, 1999,1:167-179.
|
||||||||||||||